샘플 요청 목록

 카트 문의
시장보고서
상품코드
1513895

세계의 섬유근육통 치료제 시장

Fibromyalgia Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 263 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

섬유근육통 치료제 세계 시장은 2030년까지 38억 달러에 달할 전망

2023년에 31억 달러로 추정되는 섬유근육통 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 3.0%로 성장하고, 2030년에는 38억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항간질약 약제 클래스별은 CAGR 2.8%로 성장을 지속하고, 분석 기간 종료 시에는 21억 달러에 달할 것으로 예측됩니다. 항우울제 등급별 성장률은 분석 기간 동안 CAGR 3.4%로 추정됩니다.

미국 시장은 8억 2,930만 달러로 추정, 중국은 CAGR 5.0%로 성장 예측

미국의 섬유근육통 치료제 시장은 2023년 8억 2,930만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 7억 3,620만 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 5.0%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.7%와 2.5%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 2.0%로 성장할 것으로 예측됩니다.

섬유근육통 치료제 - 주요 동향 및 촉진요인

섬유근육통은 미국 성인 약 400만 명의 QOL에 심각한 영향을 미치는 만성 질환이며, 주로 여성이 앓고 있습니다. 광범위한 근골격계의 통증 외에도 피로, 종종 "섬유성 안개"라는 인지 문제, 수면장애, 자극에 대한 과민성이 특징입니다. 섬유근육통의 진단은 복잡하며 환자의 병력에 대한 철저한 평가, 증상 확인, 기타 가능한 질병의 배제가 필요합니다. 섬유근육통은 종종 유전적 요인과 관련이 있으며 가족 내 유병률이 현저합니다. 섬유근육통에 대한 현재의 이해와 관리는 이 쇠약 상태를 앓고 있는 사람들을 더 잘 지원하기 위해 일반인과 전문가의 인식을 넓혀야 합니다.

섬유근육통을 관리하기 위한 치료적 접근은 다면적이며, 중추신경계에 의한 통증처리의 근본적인 부정에 대처하면서 증상을 완화하는데 중점을 두고 있습니다. 섬유근육통과 관련된 통증과 기분 증상의 관리를 위해, 프레가발린 및 듀록세틴과 같은 FDA 승인 약물이 일반적으로 처방됩니다. 그러나, 비스테로이드성 항염증제(NSAIDs), 오피오이드, 코르티코스테로이드는 일반적으로 효과가 없습니다. 다른 치료법으로는 신경통에 대한 가바펜티노이드, 수면장애에 대한 진정제, 정신 증상의 관리에 대한 SNRI 및 SSRI 등이 있습니다. 물리치료, 침술, 인지행동요법, 식생활 개선 등 비약물요법도 종합적인 치료계획에 빠뜨릴 수 없는 요소입니다. 이러한 전략은 전반적인 신체 기능 개선, 통증 완화, 섬유근통 환자의 삶의 질 향상을 목표로 합니다.

섬유근육통 치료제의 성장은 몇 가지 중요한 요인에 의해 견인됩니다. 진단기술의 진보는 섬유근육통의 진단의 정확성과 적시성을 향상시키고, 대상 치료의 적용을 강화하고 있습니다. 건강 관리에서 AI와 머신러닝의 통합은 맞춤 치료 계획을 촉진하고 치료 성과를 최적화합니다. 중요한 건강 지표를 모니터링하는 웨어러블 의료 기술은 실시간 데이터를 기반으로 치료 방법을 사용자 정의하는 데 도움이 됩니다. 게다가, 원격 의료 서비스의 가용성이 증가함에 따라, 특히 원격지 환자들에게는 치료 접근성이 확대되고, 치료 요법의 어드레싱이 향상되었습니다. 또한, 대체 요법에 대한 환자의 선호도 증가를 반영하여 비 약물 치료로의 전환도 두드러집니다. 또한, 섬유근육통의 조기 진단과 효과적인 관리를 촉진하기 위해서는 교육적 노력과 인지도 향상이 필수적입니다. 또한 혁신적인 치료법의 채용을 촉진하고 치료를 보다 친숙하고 저렴하게 만드는 데 있어서 규제 당국의 지원과 유리한 상환 정책도 중요한 역할을 하고 있습니다. 이러한 요인들이 결합되어 섬유근육통 치료제에서는 보다 역동적이고 통합된 환자 중심의 상황이 형성되고 있습니다.

조사 대상 기업 예(총 22건)

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.07.24

Global Fibromyalgia Therapeutics Market to Reach US$3.8 Billion by 2030

The global market for Fibromyalgia Therapeutics estimated at US$3.1 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiepileptics Drug Class, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Antidepressants Drug Class segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$829.3 Million While China is Forecast to Grow at 5.0% CAGR

The Fibromyalgia Therapeutics market in the U.S. is estimated at US$829.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$736.2 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Fibromyalgia Therapeutics - Key Trends and Drivers

Fibromyalgia is a chronic condition that significantly impacts the quality of life of about 4 million adults in the United States, primarily affecting women, though not exclusively. It is characterized by widespread musculoskeletal pain accompanied by fatigue, cognitive issues often referred to as "fibro fog," sleep disturbances, and heightened sensitivity to stimuli. The diagnosis of fibromyalgia is complex, typically involving a thorough assessment of patient history, symptom checks, and the exclusion of other potential conditions, given there are no definitive tests for fibromyalgia. The condition is often related to genetic factors, with a noticeable prevalence in families, and can be triggered by significant stress or traumatic events. Current understanding and management of fibromyalgia require a broadening of public and professional perception to better support those affected by this debilitating condition.

The therapeutic approach to managing fibromyalgia is multifaceted, focusing on alleviating symptoms while addressing the underlying irregularities in pain processing by the central nervous system. FDA-approved medications like pregabalin and duloxetine are commonly prescribed to manage pain and mood symptoms associated with fibromyalgia. Non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and corticosteroids, however, are generally ineffective. Other treatments include gabapentinoids for nerve pain, sedatives for sleep disturbances, and SNRIs and SSRIs for managing psychological symptoms. Non-pharmacological treatments such as physical therapy, acupuncture, cognitive behavioral therapy, and lifestyle modifications like dietary changes are also essential components of a comprehensive treatment plan. These strategies aim to improve overall physical function, reduce pain, and enhance quality of life for fibromyalgia patients.

The growth in fibromyalgia therapeutics is driven by several key factors. Advancements in diagnostic technologies have improved the accuracy and timeliness of fibromyalgia diagnosis, enhancing the application of targeted treatments. The integration of AI and machine learning in healthcare facilitates personalized treatment plans, optimizing therapy outcomes. Wearable health technology that monitors vital health metrics has become instrumental in customizing treatment approaches based on real-time data. Additionally, increased availability of telemedicine services has expanded access to care, particularly for patients in remote areas, improving adherence to treatment regimens. There is also a notable shift towards non-pharmacological treatments, reflecting a growing patient preference for alternative therapies. Furthermore, educational initiatives and increased awareness are crucial in promoting early diagnosis and effective management of fibromyalgia. Regulatory support and favorable reimbursement policies also play significant roles in encouraging the adoption of innovative therapies, making treatments more accessible and affordable. Collectively, these factors are shaping a more dynamic, integrated, and patient-centric landscape in fibromyalgia therapeutics.

Select Competitors (Total 22 Featured) -

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Fibromyalgia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness about Chronic Pain Disorders Throws the Spotlight on Fibromyalgia Therapeutics
    • Rising Prevalence of Fibromyalgia Propels Growth in Therapeutics Market
    • Advances in Pain Management Techniques Drive Adoption of New Therapies
    • Expanding Research on Neuropathic Pain Expands Addressable Market Opportunity
    • Innovations in Drug Delivery Systems Generate Demand for Advanced Therapeutics
    • Increasing Focus on Personalized Medicine Accelerates Demand for Targeted Fibromyalgia Treatments
    • Growing Adoption of Complementary and Alternative Medicine (CAM) Sustains Market Growth
    • Shifts in Patient Preferences towards Non-Opioid Treatments
    • Role of Telemedicine in Managing Fibromyalgia Here's the Story
    • Economic Factors and Healthcare Spending Propel Market Expansion
    • Adoption of Digital Health Technologies and Apps Expands Usage of Fibromyalgia Therapies
    • Growing Focus on Patient Education and Support Groups Propel Market Demand
    • Rising Investment in Biotechnology and Pharmaceuticals Strengthens the Business Case for Fibromyalgia Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fibromyalgia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiepileptics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제